

I. AMENDMENTS TO THE CLAIMS

Claims 1 to 10. (Canceled)

Claim 11. (Currently Amended) Compounds or their salts having the following general formula (I):



wherein:

A = ~~[[R-T1-]]~~ R-T₁-, wherein:

R is the radical of a drug having formula R-T₁-H or R-T₁-OH selected from the group of anti-inflammatory drugs consisting of acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin, zomepirac, and tomoxiprol;

~~[[T1]]~~ T₁ = (CO) or X wherein:

X = ~~[[0]]~~ O, S, N, NR_{1C} wherein:

R_{1C} is H or a linear or branched C₁-C₅ alkyl;

B = -T_B-X₂-T_{B1}- wherein:


T_B and T_{B1} are equal or different, and

T_B = (CO) when T₁ is X,

T_B = X when T₁ is (CO), X being as above defined;

T_{B1} = (CO) or X, X being as above defined, and

wherein -T_B-X₂-T_{B1}- is selected from the group consisting of



C is the bivalent radical $-T_C-Y-$ wherein:

$T_C = (CO)$ when T_{B1} is X, or

$T_C = X$ when T_{B1} is (CO) , X being as above defined,

Y is $Y_0 =$ an alkylenoxy group $R'O$ wherein

R' is linear or branched C_1 to C_{20} alkyl.

Claim 12. (Canceled)

Claim 13. (Previously Presented) A method for the treatment of pathologies associated with stress oxidative and/or endothelial dysfunction comprising administering compounds or salts according to claim 11.

Claim 14. (Previously Presented) Pharmaceutical formulations containing as active principle the compounds or salts thereof of claim 11.